Anika Therapeutics, Inc. (ANIK) Return on equity 2016–2025
Anika Therapeutics, Inc. (ANIK) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-7.7%FY2025 · since FY2016: 14.6% → -7.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -7.7% | +28.7 pp |
| FY2024 | -36.4% | +2.7 pp |
| FY2023 | -39.1% | -33.8 pp |
| FY2022 | -5.3% | -6.6 pp |
| FY2021 | 1.4% | +10.2 pp |
| FY2020 | -8.8% | -18.2 pp |
| FY2019 | 9.4% | +2.3 pp |
| FY2018 | 7.1% | -5.0 pp |
| FY2017 | 12.1% | -2.5 pp |
| FY2016 | 14.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice